MediciNova has announced positive clinical findings from the completed two-year Phase II clinical trial of orally administered MN-166 for the treatment of multiple sclerosis.
The data showed that sustained disability progression was significantly less
likely (by approximately 50%) in those patients receiving MN-166 at either 30 or
60mg per day for 24 months than in those patients receiving the drug for 12
months (p=0.026).
